Biotechs Harness Llama Antibodies For Therapies

Scientists and drug developers are investing billions into therapies built on llama-derived 'nanobodies', Bloomberg reports, with activity centered around Belgium's Free University of Brussels and multiple biotechs including Sanofi, AstraZeneca, Eli Lilly, Confo and Inhibrx. Nanobody drugs target cancer, nerve pain and autoimmune and skin diseases; Sanofi's Cablivi and AstraZeneca's gefurulimab are notable examples. Success could broaden modular, tissue-penetrant biologic platforms but widespread blockbusters remain unproven.